OBJECTIVES: This study explores and describes real therapeutic features (prevalence, incidence, length of therapy, prescriptions, etc.), treatment effectiveness in therapy groups and management costs of MRCC patients treated with M-TOR kinase inhibitors. METHODS: The analysis used patients’ data from the National Health Insurance Fund Administration (NHIFA). Subjects were patients with a diagnosis of MRCC (with ICD-10 code C64) (14.794 such patients exist), who filled a renal cancer drug prescription between Jan 2008 and July 2011 (1.648 patients). Descriptive methods and Kaplan-Meier analysis for survival and progression free survival were applied. An assumption was made that progression free survival can be described by therapy persistence due to the features of treatment lines. RESULTS: Patients usually filled for first line therapy (mainly sunitinib) with a dose for a two-month long and second line therapy (mainly sorafenib) with a dose for one-month long period at one time. Number of sunitinib patients grew significantly during the analysis period mainly due to new patients. A huge proportion of patients discontinued the therapy within three months, which shows a high ratio of non-responsive patients. Comparison of different therapies, examination of progression free survival curves, showed that first line therapies (sunitinib) have longer persistence than second line therapies (sorafenib). Therapy persistence was generally shorter than the period in which patients were on therapy based on filling of therapies. Progression free survival was longer in case of patients who were on a therapy for at least 11 months. Difference between therapies in ordinary survival couldn’t be showed due to the short period of analysis. CONCLUSIONS: Main part of patients is non-responsive to MRCC therapies in Hungary. We found that there is a difference between MRCC therapies in progression free survival of MRCC patients.